June 1, 2009
By:Jill Wechsler
Agency officials and sponsors anticipate stiffer oversight of research operations and disclosure requirements.
 |
May 1, 2009
By:Jill Wechsler
Government funding slated to boost studies comparing medications to other treatments.
|
April 1, 2009
By:Jill Wechsler
Biomedical research community finds privacy policies add cost and complexity to clinical studies.
|
March 1, 2009
By:Jill Wechsler
Reformers seek disclosure of investigator payments and conflicts of interest.
|
February 1, 2009
By:Jill Wechsler
Proposals to reduce outlays for drugs could limit biomedical research and product development.
|
January 1, 2009
By:Jill Wechsler
More resources and new leadership could help FDA regain its stature and bolster support for innovation.
|
December 1, 2008
By:Jill Wechsler
A comprehensive listing of U.S. departments and offices that includes the telephone numbers of directors, commissioners, and advisors.
|
November 1, 2008
By:Jill Wechsler
Efficient R&D is the goal of many partnerships to develop biomarkers and modernize research.
|
October 1, 2008
By:Jill Wechsler
Can larger clinical trials detect more safety problems before a drug comes to market and thus avoid serious adverse events in larger subject populations?
|
| 
